January 14, 2022

Psychedelics Approval in Canada | COMPASS Pathways $CMPS

Midas Letter
Midas Letter
Psychedelics Approval in Canada | COMPASS Pathways $CMPS
/

George Goldsmith, Chief Executive Officer of COMPASS Pathways PLC (NASDAQ:CMPS) joins James west to discuss Psycadelics approval in Canada.

Several years ago co-founders, George Goldsmith and Ekaterina Malievskaia, experienced the painful effects of depression within their own family. They discovered first-hand how hard it can be to find adequate mental health care for a loved one, and met many other patients and families who felt similarly helpless.

Motivated to find a new approach to mental health care, together with third co-founder Lars Christian Wilde, they started COMPASS with a commitment to putting patients at the heart of the company’s purpose.

Compass Pathways’ develop clinical research programme using recommended scientific processes from regulatory agencies. Their goal is to collaborate with others to advance science that could lead to improved patient outcomes and ensure their therapies are accessible and affordable to all who might be helped by them.

Related Articles

Disclosure

Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.

Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.

Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.